Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects

AbstractBackground  Recent studies of conventional chemotherapeutic drugs administered in metronomic therapy schedules showed remarkable inhibitory effects on tumor angiogenesis. Subsequent and prolonged tumor regression was achieved moreover by circumventing acquired drug resistance. In this study, metronomic and conventional trofosfamide were compared on human NSCLC xenograft “LX-1.”